Difference between revisions of "CD56"
Jump to navigation
Jump to search
(→Others) |
m (myeloma) |
||
(6 intermediate revisions by one other user not shown) | |||
Line 1: | Line 1: | ||
'''CD56''' is a commonly available [[immunostain]] that is seen in a number of tumours. It is a sensitive marker of neuroendocrine differentiation. | '''CD56''' is a commonly available [[immunostain]] that is seen in a number of tumours. It is a sensitive [[neuroendocrine marker|marker of neuroendocrine differentiation]]. | ||
==Positive== | ==Positive== | ||
Line 12: | Line 12: | ||
*[[Extranodal NK/T-cell lymphoma, nasal type]]. | *[[Extranodal NK/T-cell lymphoma, nasal type]]. | ||
*[[Hepatosplenic T-cell lymphoma]]. | *[[Hepatosplenic T-cell lymphoma]]. | ||
*[[Plasma cell myeloma]] | |||
===Others=== | ===Others=== | ||
*[[Rhabdomyosarcoma]].<ref name=pmid18487991>{{Cite journal | last1 = Bahrami | first1 = A. | last2 = Gown | first2 = AM. | last3 = Baird | first3 = GS. | last4 = Hicks | first4 = MJ. | last5 = Folpe | first5 = AL. | title = Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabdomyosarcoma: a potentially serious diagnostic pitfall. | journal = Mod Pathol | volume = 21 | issue = 7 | pages = 795-806 | month = Jul | year = 2008 | doi = 10.1038/modpathol.2008.86 | PMID = 18487991 }}</ref> | |||
*[[Solid pseudopapillary tumour]]. | *[[Solid pseudopapillary tumour]]. | ||
*[[Follicular dendritic cell sarcoma]]. | *[[Follicular dendritic cell sarcoma]]. | ||
==Occasionally positive== | |||
*[[Renal cell carcinoma]] ~18% of cases.<ref name=pmid20462442>{{cite journal |authors=Ronkainen H, Soini Y, Vaarala MH, Kauppila S, Hirvikoski P |title=Evaluation of neuroendocrine markers in renal cell carcinoma |journal=Diagn Pathol |volume=5 |issue= |pages=28 |date=May 2010 |pmid=20462442 |pmc=2876076 |doi=10.1186/1746-1596-5-28 |url=}}</ref> | |||
==See also== | ==See also== |
Latest revision as of 22:39, 26 March 2021
CD56 is a commonly available immunostain that is seen in a number of tumours. It is a sensitive marker of neuroendocrine differentiation.
Positive
Carcinomas
Lymphoid
- Acute myeloid leukemia.[2]
- Chronic myeloid leukemia.[2]
- Extranodal NK/T-cell lymphoma, nasal type.
- Hepatosplenic T-cell lymphoma.
- Plasma cell myeloma
Others
Occasionally positive
- Renal cell carcinoma ~18% of cases.[4]
See also
References
- ↑ Kurokawa, M.; Nabeshima, K.; Akiyama, Y.; Maeda, S.; Nishida, T.; Nakayama, F.; Amano, M.; Ogata, K. et al. (May 2003). "CD56: a useful marker for diagnosing Merkel cell carcinoma.". J Dermatol Sci 31 (3): 219-24. PMID 12727026.
- ↑ 2.0 2.1 URL: http://www.nordiqc.org/Epitopes/CD56/CD56.htm. Accessed on: September 13, 2014.
- ↑ Bahrami, A.; Gown, AM.; Baird, GS.; Hicks, MJ.; Folpe, AL. (Jul 2008). "Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabdomyosarcoma: a potentially serious diagnostic pitfall.". Mod Pathol 21 (7): 795-806. doi:10.1038/modpathol.2008.86. PMID 18487991.
- ↑ Ronkainen H, Soini Y, Vaarala MH, Kauppila S, Hirvikoski P (May 2010). "Evaluation of neuroendocrine markers in renal cell carcinoma". Diagn Pathol 5: 28. doi:10.1186/1746-1596-5-28. PMC 2876076. PMID 20462442. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876076/.